A New Weapon in the Fight Against Cardiometabolic Disease?
TRANSCEND-T2D-1 has yielded impressive results! Early top-line data from the first phase III trial of Lilly’s novel retatrutide shows it significantly reduces both HbA1c and body weight in type 2 diabetes patients.
This "triple agonist"—acting on GIP, GLP-1, and glucagon receptors—also improved cardiovascular risk factors like cholesterol and blood pressure. It’s an exciting step forward in changing how we manage cardiometabolic disease.
#References
* Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of type 2 diabetes
* Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.